Diligence memo · auto-generated · as of July 2, 2026

Imagine Pharma Llc

Imagine Pharma Llc looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Imagine Pharma Llc operates in Biotechnology, based in PITTSBURGH.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Imagine Pharma Llc has raised $650K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $350K on 2022-07-18.

Most recent recorded round closed around 2022-12-30.

Valuation (modeled)modeled

Provath models Imagine Pharma Llc at approximately $3.5M (range $160K–$19M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.09× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (109% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 5 months.

Last raise 3.5 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 1.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 13% of Biotechnology peers (4293 compared).

Modeled value ranks above 8% of those peers.

Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.